Walgreens Boots Alliance (NASDAQ:WBA) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a report released on Tuesday.

Several other analysts also recently weighed in on WBA. UBS reissued a “buy” rating and set a $96.00 target price (down previously from $97.00) on shares of Walgreens Boots Alliance in a research report on Wednesday, August 23rd. Royal Bank of Canada assumed coverage on shares of Walgreens Boots Alliance in a research note on Tuesday, September 19th. They set an “outperform” rating and a $96.00 price objective for the company. Jefferies Group restated a “buy” rating and set a $95.00 price objective on shares of Walgreens Boots Alliance in a research note on Monday, October 2nd. Deutsche Bank assumed coverage on shares of Walgreens Boots Alliance in a research note on Monday, December 4th. They set a “hold” rating and a $78.00 price objective for the company. Finally, Raymond James Financial restated a “market perform” rating on shares of Walgreens Boots Alliance in a research note on Wednesday, September 27th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $86.47.

Walgreens Boots Alliance (NASDAQ WBA) traded up $0.33 during trading hours on Tuesday, reaching $71.88. 6,421,200 shares of the company’s stock traded hands, compared to its average volume of 5,467,607. The stock has a market cap of $70,859.95, a P/E ratio of 14.03, a PEG ratio of 1.28 and a beta of 1.22. Walgreens Boots Alliance has a 12 month low of $63.82 and a 12 month high of $88.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.59 and a current ratio of 1.07.

Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Wednesday, October 25th. The pharmacy operator reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.10. The company had revenue of $30.15 billion for the quarter, compared to the consensus estimate of $29.93 billion. Walgreens Boots Alliance had a net margin of 3.45% and a return on equity of 18.36%. Walgreens Boots Alliance’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.07 EPS. research analysts anticipate that Walgreens Boots Alliance will post 5.54 earnings per share for the current fiscal year.

Walgreens Boots Alliance declared that its board has initiated a stock repurchase plan on Wednesday, October 25th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the pharmacy operator to repurchase shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

In related news, Director William C. Foote sold 2,736 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $67.37, for a total value of $184,324.32. Following the completion of the transaction, the director now directly owns 16,415 shares in the company, valued at approximately $1,105,878.55. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Anthony Lederer bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 26th. The stock was purchased at an average price of $67.00 per share, with a total value of $1,340,000.00. Following the completion of the purchase, the director now owns 50,000 shares in the company, valued at $3,350,000. The disclosure for this purchase can be found here. Insiders own 14.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of WBA. Commonwealth Bank of Australia grew its holdings in shares of Walgreens Boots Alliance by 139.5% during the second quarter. Commonwealth Bank of Australia now owns 46,167 shares of the pharmacy operator’s stock worth $3,614,000 after buying an additional 26,893 shares in the last quarter. IBM Retirement Fund grew its holdings in shares of Walgreens Boots Alliance by 88.1% during the second quarter. IBM Retirement Fund now owns 22,903 shares of the pharmacy operator’s stock worth $2,004,000 after buying an additional 10,729 shares in the last quarter. Andra AP fonden grew its holdings in shares of Walgreens Boots Alliance by 35.3% during the second quarter. Andra AP fonden now owns 58,300 shares of the pharmacy operator’s stock worth $4,565,000 after buying an additional 15,200 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Walgreens Boots Alliance by 5.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 3,019,739 shares of the pharmacy operator’s stock worth $236,476,000 after buying an additional 154,995 shares in the last quarter. Finally, Birinyi Associates Inc. grew its holdings in shares of Walgreens Boots Alliance by 9.0% during the second quarter. Birinyi Associates Inc. now owns 9,100 shares of the pharmacy operator’s stock worth $713,000 after buying an additional 750 shares in the last quarter. 61.41% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Walgreens Boots Alliance (WBA) Upgraded by Vetr to “Strong-Buy”” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/12/walgreens-boots-alliance-wba-upgraded-by-vetr-to-strong-buy.html.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Walgreens Boots Alliance (NASDAQ:WBA)

Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.